MZL
Advertisement
Two surrogate markers predicted treatment effect on eight-year progression-free survival in patients with extranodal MZL.
The phase I/II study examined the use of the Bruton’s tyrosine kinase inhibitor in 385 patients.
Umbralisib was approved to treat marginal zone lymphoma (MZL) and follicular lymphoma (FL).
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.